Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
CitationActa Obstet Gynecol Scand 2012, 91(7):769-78
AbstractNew studies about the influence of hormonal contraception on the risk of venous thromboembolism (VTE) have been published. To evaluate new epidemiological data and to propose clinical consequences. A literature survey. Studies assessing the risk of specific types of hormonal contraception were evaluated, compared and set into a clinical perspective. The majority of newer studies have demonstrated a threefold increased risk of VTE in current users of medium- and low-dose combined oral contraceptives (COCs) with norethisterone, levonorgestrel (LNG) or norgestimate compared with non-users. The same studies have demonstrated a sixfold increased risk of VTE in users of combined pills with desogestrel, gestodene, drospirenone or cyproteroneacetate, and in users of the contraceptive vaginal ring, compared with non-users. The rate ratio of VTE between users of COCs with newer progestogens compared with users of COCs with LNG was 1.5-2.8 in seven studies and 1.0 in two studies. Progestogen-only contraception did not confer an increased risk of VTE in any study. The incidence rate of VTE in non-pregnant women aged 15-49 years using non-hormonal contraception is three per 10 000 years. For women starting on hormonal contraception, we recommend medium- or low-dose combined pills with norethisterone, LNG or norgestimate as first-choice preparations. For the many women who are users of COCs with newer progestogens, although the absolute risk of VTE is low, a change to combined pills with norethisterone, LNG or norgestimate may halve their risk of VTE. Finally, we recommend COCs with 20 μg estrogen combined with the older progestogens to be launched in the Scandinavian countries. Women at an increased risk of VTE should consider progestogen-only contraception or non-hormonal contraception.
DescriptionTo access publisher's full text version of this article. Please click on the hyperlink in Additional Links field.
RightsArchived with thanks to Acta obstetricia et gynecologica Scandinavica
- Combined hormonal contraception and venous thromboembolism.
- Authors: Martínez F, Avecilla A
- Issue date: 2007 Jun
- Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
- Authors: Jick SS, Kaye JA, Russmann S, Jick H
- Issue date: 2006 Jun
- Thrombotic risks of oral contraceptives.
- Authors: Rott H
- Issue date: 2012 Aug
- Epidemiology of hormonal contraceptives-related venous thromboembolism.
- Authors: Hugon-Rodin J, Gompel A, Plu-Bureau G
- Issue date: 2014 Dec
- European Society of Contraception oral contraceptives survey update: birth control methods in "Europe of the 12".
- Authors: Serfaty D, Wildemeersch D, Verougstraete A, Creatsas G
- Issue date: 1995